News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
The FDA has approved emergency use authorization for AstraZeneca’s Evusheld cocktail as prophylaxis against COVID-19 infection in adults and adolescents aged at least 12 years.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Newpath is guided by the ethos: “Do the right thing and good things will happen.”
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.
At Harbinger, Hahn will oversee the development of the Bio-AI diagnostics platform dubbed HarbingerHx, in hopes of detecting cancer in a patient before it is visible or symptomatic.
The counterclaim by an alleged victim of MIT professor David Sabatini said she was coerced into sex and that Sabatini’s laboratory had a “toxic and sexually charged” environment.
Vyera Pharmaceuticals agreed to pay $40 million to settle federal allegations to radically increase the price of toxoplasmosis drug Daraprim and prevent generic competition.